News | July 06, 2022
Wacker to expand mRNA-based actives capacity at Halle, Germany
Company is investing more than €100 million in the expansion of the Halle site
Company is investing more than €100 million in the expansion of the Halle site
The new facility is scheduled to start operation in the first half of 2024
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Subscribe To Our Newsletter & Stay Updated
